Format

Send to

Choose Destination
Am J Transplant. 2017 Aug;17(8):1974-1991. doi: 10.1111/ajt.14238. Epub 2017 Apr 10.

Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients.

Author information

1
Houston Methodist Hospital, Houston, TX.
2
The University of Texas MD Anderson Cancer Center, Houston, TX.

Abstract

It is estimated that solid organ transplant recipients have a two- to fourfold greater overall risk of malignancy than the general population. Some of the most common malignancies after transplant include skin cancers and posttransplant lymphoproliferative disorder. In addition to known risk factors such as environmental exposures, genetics, and infection with oncogenic viruses, immunosuppression plays a large role in the development of cancer through the loss of the immunosurveillance process. The purpose of this article is to explain the role of immunosuppression in cancer and to review the classes of chemotherapeutics. The field of anticancer drugs is continually expanding and developing, with limited data on use in transplant recipients. This article aims to provide information on class review, adverse effects, dose adjustments, and drug interactions that are pertinent to the care of transplant recipients.

KEYWORDS:

cancer/malignancy/neoplasia: chemotherapy; clinical research/practice; immunosuppressant; immunosuppression/immune modulation; pharmacology

PMID:
28394486
DOI:
10.1111/ajt.14238
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center